Executive Board
The Executive Board has been established to assist the Chief Executive in leading The Institute of Cancer Research to achieve its strategic aims and objectives within the approved strategies and budgets and is responsible for formulating strategies, plans and budgets for approval by the Board of Trustees.
Professor Kristian Helin
Chief Executive and President
Professor Kevin Harrington
Head of Division – Radiotherapy and Imaging
Professor Clare Isacke
Dean of Academic and Research Affairs
Paul Norris
Chief Financial Officer
Jonathan Monk
Chief Information Officer
Professor Jonathon Pines
Head of Division – Cell and Molecular Biology
Dr Barbara Pittam
Chief Research and Academic Officer
Dr Olivia Rossanese
Head of Division – Cancer Therapeutics
Dr Kary Kelly
Chief Development and Communications Officer
Latest ICR News
The ICR and The Royal Marsden partner with Mint Medical on roll out of global AI cancer imaging tool
The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have announced a new licensing agreement with MedTech company Mint Medical, a Snke Company, to improve monitoring for patients with bone disease in advanced prostate cancer and multiple myeloma.
Targeting cancer cell DNA repair mechanism may make radiotherapy more effective
Scientists have uncovered a mechanism that helps cancer cells survive radiation, pointing to a potential new way to make treatment more effective.
ICR welcomes FDA approval of capivasertib for advanced prostate cancer
The Institute of Cancer Research, London, strongly welcomes the news that the targeted drug capivasertib, has been approved by the US Food and Drug Administration (FDA) for treating a type of advanced prostate cancer.
---945x532.jpg?sfvrsn=73000500_2 "radiotherapy IMRT (photo: Jan Chlebik/the ICR) - 945x532")
Thousands of men with prostate cancer will now be offered high-powered radiotherapy on the NHS
Thousands of men with prostate cancer in England will be offered a more precise form of radiotherapy that cuts treatment time by up to 75 per cent, based on the results of a trial led by The Institute of Cancer Research (ICR), London and Royal Marsden NHS Foundation Trust. The therapy is known as SABR or SBRT.